IBA, Ltd., secondary image

Institute of Biostatistics and Analyses

Spin-off company of the Masaryk University

Institute of Biostatistics and Analyses (IBA) is a spin-off company of the Masaryk University, with a share of ownership by the Masaryk University.

The company focuses mainly on the areas of project management of clinical research, real-world evidence (RWE) projects, organisation and management of clinical trials, particularly non-interventional clinical trials and health registries. This main activity is complemented with other services such as market access support, cost-effectiveness analysis, pharmacovigilance, analysis of clinical data, development of tailored software products and graphic design.

About us
Clinical projects and research
Clinical projects & research
ICT systems
ICT systems
Registry.cz
Registry.cz
Data analysis
Data analysis

News

Conference on Clinical Studies
May 29-30th  2024

Marika Crápavá will be one of the main speakers at the prestigious The 3rd Conference on Clinical Studies with Medical Devices and IVDs (CSMD2024)

Participation in conferences
April 12th  2024

The end of the year is marked by conferences where we participate either as participants, speakers or co-organizers.

MEFANET 2023
November 13th  2022

Daniel Schwarz chaired this year's MEFANET conference, which took place in Košice on 7-8 November 2023.The latest knowledge and experience in the field of modern technologies and innovations in medical education were presented at the conference.

Quality management

Pharmacovigilance

Web studio

Real-world evidence/data

The Institute of Biostatistics and Analyses is an investigator of the project “Extending services portfolio of an information system for the data management in clinical research”. The project is supported by the OP EIC from the European Union funds.

Main objective of the project is the development of a platform for composition of information systems focused on data management and data mining in the field of pharmaceutical industry and life sciences. Offer of digital services based on a developed and validated information system will make reliable analytical models accessible to the companies for their decision-making and precise information sources for regulatory bodies. The project steps out of a laboratory environment of clinical trials and focuses on the evidence supported by real-world data.

Institute of Biostatistics and Analyses, Ltd.